DDInter948 DDInter1744
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977.
Tamoxifen {u} (Compound) resembles {v} (Compound) Methadyl Acetate
Tamoxifen {u} may lead to a major life threatening interaction when taken with {v} Dextropropoxyphene
Tamoxifen {u} (Compound) resembles {v} (Compound) Naftifine
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loperamide
Tamoxifen {u} may lead to a major life threatening interaction when taken with {v} Diphenhydramine
Tamoxifen {u} (Compound) treats {v} (Disease) breast cancer
Tamoxifen {u} (Compound) binds {v} (Gene) CYP2E1
Tamoxifen {u} (Compound) upregulates {v} (Gene) SC5D
Tamoxifen {u} (Compound) downregulates {v} (Gene) CCNB2
Tamoxifen {u} (Compound) causes {v} (Side Effect) Thirst
Tamoxifen (Compound) resembles Methadyl Acetate (Compound)
Tamoxifen may lead to a major life threatening interaction when taken with Dextropropoxyphene
Tamoxifen (Compound) resembles Naftifine (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Tamoxifen may lead to a major life threatening interaction when taken with Diphenhydramine
Tamoxifen (Compound) treats breast cancer (Disease)
Tamoxifen (Compound) binds CYP2E1 (Gene)
Tamoxifen (Compound) upregulates SC5D (Gene)
Tamoxifen (Compound) downregulates CCNB2 (Gene)
Tamoxifen (Compound) causes Thirst (Side Effect)